To receive daily emails from Breaking Christian News to your inbox CLICK HERE


SHARE THIS ARTICLE Printer friendly version of this page

"Life-Changing Day" for Migraine Sufferers as FDA Approves First-Ever Drug to Prevent Chronic Headaches

News Staff : May 18, 2018  FDA

It's a once-a-month injection, effective for people who suffer from migraines at least four days a month.

airlift(Washington, DC)—[FDA.gov] The U.S. Food and Drug Administration today approved Aimovig for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks. (Image credit: Miss Rogue-Flickr)

"Aimovig provides patients with a novel option for reducing the number of days with migraine," said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "We need new treatments for this painful and often debilitating condition."

Patients often describe migraine headache pain as an intense pulsing or throbbing pain in one area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. Approximately one-third of affected individuals can predict the onset of a migraine because it is preceded by an aura—transient sensory or visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, hormonal changes, bright or flashing lights, lack of food or sleep and diet. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide.

The effectiveness of Aimovig for the preventive treatment of migraine was evaluated in three clinical trials. The first study included 955 participants with a history of episodic migraine and compared Aimovig to placebo. Over the course of six months, Aimovig-treated patients experienced, on average, one to two fewer monthly migraine days than those on placebo. The second study included 577 patients with a history of episodic migraine and compared Aimovig to placeb.
Over the course of three months, Aimovig-treated patients experienced, on average, one fewer migraine day per month than those on placebo. The third study evaluated 667 patients with a history of chronic migraine and compared Aimovig to placebo. In that study, over the course of three months, patients treated with Aimovig experienced, on average, 2 ½ fewer monthly migraine days than those receiving placebo.

The most common side effects that patients in the clinical trials reported were injection site reactions and constipation.

The FDA granted the approval of Aimovig to Amgen Inc.







SHARE THIS ARTICLE Printer friendly version of this page

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Other Recent Articles from Breaking Christian News

The 'Audacious' Story of How Anti-Trafficking Organization, Born2Fly International Began: an Interview with Founder Diana Scimone

End of Realtor Commission Model Poses Biggest 'Jolt' in Housing in 100 Years

Finnish Study: 'Woke' People More Likely to be Unhappy, Anxious and Depressed.' No Kidding.

New Film 'Epidemic of Fraud' Exposes Massive COVID Corruption

Shameful Senator Schumer Provides Cover for Biden's Smears of Israel

REGIME MEDIA: ABC World News Tonight Advances the Bloodbath Hoax

Supreme Court Unanimously Rules That Public Officials Can Be Sued for Blocking Critics on Social Media

REPORT: Self-Proclaimed Hezbollah Terrorist Arrested at Border in Texas, Was Heading to New York to 'Make a Bomb'

Trudeau's Online Harms Bill Threatens Canadians' Basic Rights, Pro-freedom Group Warns

Fifth Circuit Court Upholds Texas Age-Verification Law Restricting Porn Site Access

Sickening: Kamala Harris Visits a Planned Parenthood Facility in Pro-Abortion Tour

Tennessee House Passes Bill Requiring Fetal Development Video in Public Schools

Led by Riley Gaines, 16 Women File Groundbreaking Suit against the NCAA: 'We Are Standing for Women's Sports'

Elon Musk, Matt Walsh Highlight Study Showing Transgender Surgeries Double Risk of Suicide

Boeing Whistleblower Who Died Suspiciously Said This to His Friend before His Death: 'If Anything Happens to Me, It's Not Suicide' (VIDEO)

Breitbart Exclusive—Donald Trump: Joe Biden Has Shown 'No Compassion' to Laken Riley's Family, Only Said Her Name Incorrectly after MTG Pressure

'Justice Denied': Judge Rules That Fani Willis Can Continue to Prosecute Donald Trump

West Point Removes 'Duty, Honor, Country' from Its Mission Statement

Ghana's Parliament Passes Anti-'LGBTQ' Law

NHS England: Children Will No Longer Receive Puberty Blockers Unless In Clinical Trials



Search the Articles Archives

Keyword:  
Author:  
Words Posted On:  
Day Month Year



BCN Plus

Follow BCN on Twitter
Are You Praying for Our Government Leaders?
BCN Staff

Steve Shultz
Steve Shultz, Managing Editor
Founder and Owner


Aimee Herd
Aimee Herd, Editor


BCN Plus
Are You Praying for President Trump?
 
 

All articles on this site and emails from BCN are copyrighted property of Breaking Christian News. Permission is given to link to, or share a BCN story if proper attribution is given to both the original writer and summarizer of the story. Breaking Christian News 2005-2019. All Rights Reserved.


Breaking Christian News is a division of Elijah List Publications, Inc. All Rights Reserved


Disclaimer: Articles and links, as well as the source articles linked to; do not necessarily reflect the opinion of Breaking Christian News.

editor@breakingchristiannews.com